Humacyte is trading 10.9% down at $0.59 after its August 12, 2026, second-quarter results missed analyst expectations.
- EPS was -$0.16 versus -$0.09 expected, while revenue was $410,000 versus $1.11 million forecast.
- Commercial Symvess sales rose year over year to $0.4 million but remained modest; management provided no specific 2026 revenue or EPS guidance.
- The broader market was positive, indicating a company-specific reaction.